首页> 外文期刊>The clinical journal of pain >The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.
【24h】

The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.

机译:5%的利多卡因贴剂可有效治疗所有神经性疼痛质量:使用神经性疼痛量表进行的一项随机,双盲,载体对照,为期3周的疗效研究的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND Several controlled clinical trials have demonstrated the efficacy and safety of the lidocaine patch 5% (LP) for the treatment of postherpetic neuralgia (PHN).OBJECTIVE To assess the effects of the LP on distinct neuropathic pain qualities common to all neuropathic pain conditions, the authors analyzed data from one of the vehicle-controlled trials in which the Neuropathic Pain Scale (NPS), the only assessment tool specifically designed to measure the distinct components of neuropathic pain, was administered.METHODS AND RESULTS To improve the sensitivity of the NPS to treatment effects, only patients who, at the time of enrollment in the study, reported moderate-to-severe pain on the NPS (as defined by a score >/=4/10 reported for at least 6 of the 10 individual NPS items) were included in the analysis. Thus, 96 patients were included in this analysis. After a 3-week, vehicle-controlled study, LP improved all assessed pain qualities to a greater extent than the placebo patch, as measured by the NPS 10, a sum score including all 10 NPS item scores ( = 0.043), and an NPS 8 score, which included scores for all 8 pain descriptors, excluding "unpleasantness" and "global intensity" ( = 0.042). Separate analysis of all 8 items believed not to reflect allodynia (NPS NA; excluding "skin sensitivity" and "surface pain") also demonstrated superiority ( = 0.022), as did analysis of the subitems that are believed not to be primarily related to peripheral pathophysiological events (the NPS 4 This study demonstrates that LP reduces the intensity of all common neuropathic pain qualities and thus may be of potential benefit for nonallodynic neuropathic pain states. Furthermore, these findings suggest that peripheral mechanisms may play a role in the pathophysiological development of pain qualities that heretofore have been assumed not to involve peripheral mechanisms, such as "dull," "deep," "sharp," and burning
机译:背景技术多项受控的临床试验已证明5%利多卡因贴剂(LP)治疗带状疱疹后神经痛(PHN)的有效性和安全性。作者分析了一项车辆对照试验的数据,该试验中使用了神经病理性疼痛量表(NPS),这是专门设计用来测量神经性疼痛不同成分的唯一评估工具。方法和结果为了提高NPS的敏感性关于治疗效果,只有在研究入组时报告中枢神经痛为中度至重度疼痛的患者(定义为得分大于/ = 4/10的患者才报告至少有10种NPS项中的6种)包含在分析中。因此,该分析包括96名患者。经过为期3周的车辆对照研究,与NPS 10,包括所有10 NPS项目评分(= 0.043)的NPS总和相比,LP改善了所有评估的疼痛质量的程度均高于安慰剂贴片。 8分,其中包括所有8种疼痛描述符的得分,不包括“不愉快”和“整体强度”(= 0.042)。对所有8个被认为不能反映异常性疼痛的项目(NPS NA;“皮肤敏感性”和“表面疼痛”除外)进行的单独分析也显示出优越性(= 0.022),对那些被认为与周围环境无关的子项目也进行了分析。病理生理事件(NPS 4这项研究表明,LP降低了所有常见神经性疼痛质量的强度,因此可能对非异常性神经性疼痛状态具有潜在的益处。此外,这些发现表明,外周机制可能在糖尿病的病理生理发展中起作用迄今为止,人们一直认为疼痛特质不涉及周围的机制,例如“沉闷”,“深度”,“尖锐”和灼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号